SV Life Sciences has announced the final closing of its newest fund, SV Life Sciences Fund V, at over $523 million, well exceeding its target of $400 million.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.